Cambridge Investment Research Advisors
BPMC

Cambridge Investment Research Advisors’s Blueprint Medicines BPMC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,500
Closed -$244K – 2112
2017
Q3 		$244K Buy
+3,500
New +$187K ﹤0.01% 1691

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Cambridge Investment Research Advisors's BPMC Position: Q4 2017 in Review

Cambridge Investment Research Advisors sold out of Blueprint Medicines (BPMC) in Q4 2017, closing a stake of 3,500 shares — an estimated $244K sold.

Cambridge Investment Research Advisors first reported a position in BPMC in Q3 2017 and held it in 1 quarter. The position peaked at $244K in Q3 2017. 170 funds tracked by Wall St. Rank hold BPMC as of Q4 2017.

  • Cambridge Investment Research Advisors reported no remaining Blueprint Medicines position as of Q4 2017 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 3,500 Blueprint Medicines shares in Q4 2017, an estimated $244K.
  • Cambridge Investment Research Advisors first reported a position in Blueprint Medicines in Q3 2017 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Blueprint Medicines position peaked at $244K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2017.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2017, filed 22 Feb 2018.